RAPP
Rapport Therapeutics, Inc. Common Stock
NASDAQ: RAPP · HEALTHCARE · BIOTECHNOLOGY
$33.00
-2.19% today
Updated 2026-04-29
Market cap
$1.58B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.86
Dividend yield
—
52W range
$8 – $42
Volume
0.3M
Rapport Therapeutics, Inc. Common Stock (RAPP) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | $15000.00 | $112000.00 | $839000.00 | $1.02M |
| Gross profit | $-15000.00 | $-112000.00 | $-839000.00 | $-1.02M |
| Gross margin | — | — | — | — |
| R&D | $9.12M | $28.00M | $60.94M | $94.79M |
| SG&A | $1.37M | $8.18M | $22.12M | $30.31M |
| Operating income | $-10.37M | $-36.18M | $-83.06M | $-125.10M |
| Operating margin | — | — | — | — |
| EBITDA | $-10.35M | $-34.66M | $-77.47M | $-124.08M |
| EBITDA margin | — | — | — | — |
| EBIT | $-10.37M | $-34.78M | $-78.31M | $-125.10M |
| Interest expense | $285000.00 | $0.00 | — | — |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-10.65M | $-34.79M | $-78.31M | $-111.48M |
| Net income growth (YoY) | — | -226.6% | -125.1% | -42.4% |
| Profit margin | — | — | — | — |